{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:05:12Z","timestamp":1789815912538,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017961","name":"Health Commission of Heilongjiang Province","doi-asserted-by":"publisher","award":["2020\u2013013"],"award-info":[{"award-number":["2020\u2013013"]}],"id":[{"id":"10.13039\/100017961","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.clinre.2022.101962","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T02:29:03Z","timestamp":1653618543000},"page":"101962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients"],"prefix":"10.1016","volume":"46","author":[{"given":"Ning","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanchuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1791-8673","authenticated-orcid":false,"given":"Xiaojun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2022.101962_bib0001","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2022.101962_bib0002","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","article-title":"Gastrointestinal stromal tumours","volume":"7","author":"Blay","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinre.2022.101962_bib0003","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41575-018-0038-1","article-title":"Adiposity and gastrointestinal cancers: epidemiology, mechanisms and future directions","volume":"15","author":"Murphy","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2022.101962_bib0004","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.21037\/atm-20-3509","article-title":"Locoregional gastric cancer: a narrative review of multidisciplinary management","volume":"8","author":"Pelcovits","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clinre.2022.101962_bib0005","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev-med-081117-043436","article-title":"Gastric cancer etiology and management in Asia and the West","volume":"70","author":"Russo","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clinre.2022.101962_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092598","article-title":"Multimodality treatment in metastatic gastric cancer: from past to next future","volume":"12","author":"Parisi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clinre.2022.101962_bib0007","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.3748\/wjg.v25.i38.5773","article-title":"Targeted therapies in metastatic gastric cancer: current knowledge and future perspectives","volume":"25","author":"Pellino","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinre.2022.101962_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818808072","article-title":"New drug developments in metastatic gastric cancer","volume":"11","author":"Tan","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.clinre.2022.101962_bib0009","first-page":"10","article-title":"The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer","volume":"39","author":"Wang","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.clinre.2022.101962_bib0010","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.2147\/CMAR.S249153","article-title":"Large scale, multicenter, prospective study of apatinib in advanced gastric cancer: a real-world study from China","volume":"12","author":"Peng","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clinre.2022.101962_bib0011","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2022.101962_bib0012","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinre.2022.101962_bib0013","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.clinre.2022.101962_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107694","article-title":"Combination therapy with PD-1\/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms","volume":"219","author":"Huang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinre.2022.101962_bib0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semcancer.2020.06.016","article-title":"Immune checkpoint inhibitors: key trials and an emerging role in breast cancer","volume":"79","author":"Gaynor","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clinre.2022.101962_bib0016","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2022.101962_bib0017","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinre.2022.101962_bib0018","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-20-3136","article-title":"Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy","volume":"27","author":"Zhou","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinre.2022.101962_bib0019","doi-asserted-by":"crossref","first-page":"12683","DOI":"10.2147\/OTT.S286169","article-title":"Safety and efficacy of camrelizumab combined with apatinib for advanced hepatocellular carcinoma with portal vein tumor thrombus: a multicenter retrospective study","volume":"13","author":"Yuan","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.clinre.2022.101962_bib0020","first-page":"2946","article-title":"Anti-PD-1 antibody SHR-1210 plus apatinib for metastatic colorectal cancer: a prospective, single-arm, open-label, phase II trial","volume":"10","author":"Ren","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.clinre.2022.101962_bib0021","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 Antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinre.2022.101962_bib0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/annonc\/mdy502","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS","volume":"30","author":"Muro","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinre.2022.101962_bib0023","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinre.2022.101962_bib0024","article-title":"Efficacy and safety of camrelizumab monotherapy and combination therapy for cancers: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122000961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122000961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:20Z","timestamp":1761895940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740122000961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2210740122000961"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2022.101962","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2022.101962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101962"}}